1. Type of sales or supply contract | Other sales or supply contracts | |
- Name of contract concluded | Production of Novavax's COVID-19 vaccine Prefilled Syringe(PFS) | |
2. Details of contract | Contract amount (KRW) | 39,463,468,100 |
Sales of the latest fiscal year (KRW) | 929,000,929,909 | |
Ratio to sales (%) | 4.25 | |
Classified as a large-sized corporation? | Yes | |
3. Counterparty to contract | Novavax, Inc. | |
- Relationship to company | - | |
4. Regions of sales or supply (markets served) | - | |
5. Contract period | Start date | 2022-07-18 |
End date | 2023-12-31 | |
6. Terms and conditions of contract | Novavax's PFS technology transfer and production of PFS Drug Product | |
7. Effective date of contract (receipt of orders) | 2022-07-18 | |
8. Withholding of disclosure | Reasons for withholding disclosure | - |
Withholding period | - | |
9. Other matters to be factored into investment decisions | ||
- The above contract amount is the amount obtained by applying the initial basic exchange rate (KRW 1,323.70/USD) as of July 18, 2022 to USD 29,813,000. - The above sales of the latest fiscal year is the company's sales based on the FY 2021 individual financial statements. - The above contract amount and contract period may differ depending on revisions of the contract terms by consensus. | ||
※ Related disclosure | - |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
SK Bioscience Co. Ltd. published this content on 20 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2022 07:43:05 UTC.